Novartis Discontinues Hydroxychloroquine Clinical Trial

Novartis will stop its clinical trial on using hydroxychloroquine to treat Covid-19 patients due to slow enrollment but remains committed to pandemic research efforts, it says in a statement.

• Recruitment challenge has made it unlikely that its clinical team would be able to collect meaningful data in a reasonable timeframe
• No safety issues have been reported or efficacy conclusions made
• Company says supply of hydroxychloroquine will continue for clinical trials and upon government requests worldwide
• NOTE: Hydroxychloroquine Shows No Covid-19 Benefit in U.K. Study (2)

To contact the reporter on this story:
Sebastian Tong in San Francisco at stong41@bloomberg.net ...